A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review
Authors:
Open Access
- 13 January 2020
- journal article
- case report
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 8
Abstract
Immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte–associated antigen-4 and anti-programmed death-1, are a type of cancer immunotherapy approved for late-stage malignancy treatment. However, such therapies often induce immune-related adverse events. During anti-programmed death-1 blockade therapy, the most commonly reported adverse effects are skin toxicities, such as psoriasis—a chronic immune-mediated inflammatory disorder affecting the skin. We present the clinical characteristics of flared psoriasis in one patient under anti-programmed death-1 therapy who was diagnosed with T2N2M0/IIIB squamous lung carcinoma with a history of psoriasis for the past 5 years, exacerbated after the first cycle of nivolumab. After the third cycle, the extensive skin plaques necessitated treatment cessation. Following the discontinuation of anti-programmed death-1 treatment, skin lesions were treated locally. Possibly, anti-programmed death-1 immunotherapy can trigger immune-mediated diseases, such as psoriasis. Physicians should be alert to immune-related adverse events. Continuation or permanent cessation of treatment depends on the severity and reversibility of immune-related adverse events.Keywords
This publication has 8 references indexed in Scilit:
- Anti-PD1/PDL1 induced psoriasisCurrent Problems in Cancer, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Cancer Immunotherapy, Part 1: Current Strategies and Agents.2017
- Varied immuno-related adverse events induced by immune-check point inhibitors — Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 —Japanese Journal of Clinical Immunology, 2017
- Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancerRheumatology, 2016
- Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic MelanomaActa Dermato-Venereologica, 2016
- Immunotherapy Approaches in Cancer TreatmentCurrent Pharmaceutical Biotechnology, 2015
- Psoriasis in Children and Adolescents: Diagnosis, Management and ComorbiditiesPediatric Drugs, 2015